Castleark Management’s Ascendis Pharma A/S ASND Stock Holding History

Castleark Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.5M	Sell	61,696 -5,920	-9%	-$1.38M	0.44%	41
2026 Q1	$15.5M	Buy	67,616 +1,280	+2%	+$287K	0.51%	38
2025 Q4	$14.1M	Buy	66,336 +23,680	+56%	+$4.89M	0.42%	44
2025 Q3	$8.48M	Buy	+42,656	New	+$7.96M	0.24%	81
2021 Q3	–	Sell	-3,095	Closed	-$407K	–	331
2021 Q2	$407K	Hold	3,095	–	–	0.01%	262
2021 Q1	$399K	Sell	3,095 -800	-21%	-$122K	0.01%	268
2020 Q4	$650K	Hold	3,895	–	–	0.02%	270
2020 Q3	$601K	Hold	3,895	–	–	0.02%	264
2020 Q2	$576K	Hold	3,895	–	–	0.03%	252
2020 Q1	$439K	Sell	3,895 -400	-9%	-$52K	0.03%	238
2019 Q4	$598K	Sell	4,295 -435	-9%	-$48.3K	0.02%	269
2019 Q3	$456K	Buy	4,730 +630	+15%	+$70.3K	0.02%	294
2019 Q2	$472K	Buy	+4,100	New	+$491K	0.02%	294

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Castleark Management's ASND Position: Q2 2026 in Review

Castleark Management reduced its Ascendis Pharma A/S (ASND) stake by 8.8% in Q2 2026, selling an estimated $1.38M and leaving 61,696 shares worth $16.5M. The position accounts for 0.44% of the portfolio, ranked #41.

Castleark Management first reported a position in ASND in Q2 2019 and has held it in 13 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Castleark Management held 61,696 shares of Ascendis Pharma A/S worth $16.5M as of Q2 2026.
Castleark Management sold 5,920 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.38M.
Ascendis Pharma A/S made up 0.44% of Castleark Management's portfolio in Q2 2026, its #41 holding.
Castleark Management first reported a position in Ascendis Pharma A/S in Q2 2019 and has held it in 13 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.